

Dr. rer. nat. Dr. med. Kurt-Wilhelm Stahl

60, Günterstalstr. D-79100 Freiburg

Phone office +49-761-701370 fax +49-761-701374 mobile +49—(0)160-91911291

<http://www.waisenmedizin.org/Waisenmedizin/Welcome.html>

stahlkw@orphandrug.org

OBJECTIVE: Presentation "LeiProtect®", a co-development of physicians and pharmacists to treat Cutaneous Leishmanias of the Old World economizing antimony chemotherapy"

PROFESSIONAL EMPLOYMENT

Since 2000 ongoing	Head of the non-profit NGO Waisenmedizin (WM e.V.) which promotes the orphan drug idea in terms of equity access to care with essential medicine acc. to the revised EU Social Charta, Articles 11 and 13; WM e. V. cooperates with the GLOBAL HEALTH GROUP of the University of Freiburg
Since retirement in 2003	Senior Expert listed by the Senior Expert Service (SES)
2004 - 2012	Sponsored by the German Academic Exchange Service in Afghanistan
1989 - 2003	Operating the " stahl health care " scientific consultancy for pharmaceutical products (since 1989) focussing on: Scientific product idea evaluation, innovations and their transfer, strategic product development-tal as well as regulatory advice, and expertises.
1999 - 2002	Expert to the C.I / dg13 of the EU Commission, within the 5 th (cell factory & infectious diseases / orphan drugs) & 4 th frameworks (technology validation)
Since 1989	Professor of Biochemistry in an extracurricular capacity (apl.) Medical School of Hannover.
1984 - 1989	R & D Director, Technology Park Heidelberg. Developed a novel co-mitogenic oxidant principle for promotion of wound healing and for speeding-up tissue repair in other parts of the body, (e. g. bone marrow, skin,) as an anti-iatrogenic adjunct treatment after cytostatic therapy. Also administered a federal (BMFT) grant and promoted knowledge transfer from university to industry.
1986 - 1988	Professeur Conventionné, Pharmaceutical Faculty ULP Strasbourg Lectured before students of pharmacy on immunopharmacology directed research programmes for drug development.
1983 - 1986	Senior Drug Evaluation Scientist. Evaluated new products for inlicensing purposes for various pharmaceutical SMEs.
1982 - 1983	Medical Director Midi-Labaz. Head of the Medical Department of Midi-Labaz Arzneimittel, a German pharmaceutical branch of the French multinational SANOFI. Coordinated drug risk management before the Health Authorities and clinical phase 4 trials.
1981 - 1982	Senior Scientist, Institute of Pathology, University of Freiburg. In charge of a research program analyzing DNA from rodents previously treated with alkylating carcinogens (Federal BMFT grant).
1978 - 1980	Professeur Associé U. Paris XI & Institute of Oncology Villejuif (Director Georges Mathé) Research work on macrophages and cancer granted by the Mildred Scheel Foundation and the Ligue Nationale Contre le Cancer.
1976 - 1977	Embo Senior fellow, Immunopathology, Molecular Biology (Director François Jacob) Pasteur Institute Paris. Analyzing an anti-inflammatory peptide underlying the macrophago-toxic effect of malignant cells
1975 to 1976	Post Doc Radiology Department, Medical School of HANOVER internal medicine trainee period

1967 to 1975	Post Doc & Research Assistant Biochemistry Department, Medical School of HANOVER introduced high pressure liquid chromatography into analytical biochemistry (2 patents for high pressure resistant glass columns)
1963 to 1966	Medizinalassistent, University of Freiburg Exp. Oncology / Clin. Chemistry Urban Krankenhaus, Berlin-Kreuzberg Internal Medicine / Surgery Kreiskrankenhaus Peine , Gynecology

Research interests

Reactive oxygen species (ROS) in chronic wounds, involvement of immune system in host defence and tissue regeneration, interests actually focussed on the interface between basic research and applied clinical research under cost / benefit aspects in underdeveloped countries.

Since 2004 involved in clinical studies with leishmania patients in Afghanistan elaborating trial monitoring by electronic medicine and elaboration of a standard web based protocol for leishmania patients.

Language Knowledge (WHO code)

Mother tongue in <i>italics</i>	Speak	Read	Write
English (Intermediate London Chamber of Commerce Certificate)	3	3	3
French (1 ^{er} et 2 ^{ième} degree de la Langue Française)	3	3	3
<i>German</i>	-	-	-
Spanish	3	2	2
Portuguese	1	1	1
Latin	-	1	-

Code

- 1 *Limited conversation, reading of newspapers, routine correspondence*
- 2 *Engage freely in discussions read and write more difficult material*
- 3 *Speak, read, and write nearly as in mother tongue*

Publications

50 publications, in Agents Actions, Akt. Rheumatologie, Brit. J. Dermatol., Cancer res., Eur. J. Biochem., FEBS, J. Chromatography, Lancet, PLoS NTD, Toxicol. Appl. Pharmacol., BMC

Holder of national and European patents, in the field of analytical biochemistry, diagnostics and drugs.

Publications relevant to the topic:

1. Hinz J., Hautzinger H., Stahl KW.: "Rationale for and results from a randomised, double-blind trial of tetrachloro-decaoxygen anion complex in wound healing" Lancet, 1(8485):825-8, 1986 Apr 12
2. KW Stahl in DNDi Report Paris 2006 <http://www.kinetoplastids.com/content/6/1/3>
3. KW Stahl, IG Sakhayee: „Lupoid cutaneous leishmaniasis in Afghanistan treated with 0.045% DAC N-055“ BMC Proceedings 2011, 5(Suppl 6): P247 <http://www.biomedcentral.com/content/pdf/1753-6561-5-s6-p247.pdf>
4. KW Stahl, H Darmangar: "0.045% DAC N-055 a choice for poor Afghan surgical patients?" BMC Proceedings 2011, 5(Suppl 6): P246 <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3239673/>
5. Jebran AF, Schleicher U, Steiner R, Wentker P, Mahfuz F, Stahl HC, Amin FM2, Bogdan C, and Stahl KW: „Rapid Healing of Cutaneous Leishmaniasis by High-Frequency Electrocauterization and Hydrogel Wound Care with or without DAC N-055: A Randomized Controlled Phase IIa Trial in Kabul“ PLoS NTD 2014 in press
6. Stahl HC, Ahmadi F, Schleicher U, Sauerborn R, Bermejo JL, Amirih ML, Sakhayee I, Bogdan C, Stahl KW: "A randomized phase IIb wound healing trial of cutaneous leishmaniasis ulcers with 0.045% pharmaceutical chlorite (DAC N-055) with and without bipolar high frequency electrocauterization versus intralesional antimony in Afghanistan" BMC Infect Dis. 2014 Nov 25;14:619. doi: 10.1186/s12879-014-0619-8